J. Safra Sarasin Holding AG Acquires 5,986 Shares of Zimmer Biomet Holdings, Inc. $ZBH

J. Safra Sarasin Holding AG grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 93.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,415 shares of the medical equipment provider’s stock after acquiring an additional 5,986 shares during the period. J. Safra Sarasin Holding AG’s holdings in Zimmer Biomet were worth $1,223,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Cullen Frost Bankers Inc. lifted its holdings in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares during the period. Root Financial Partners LLC bought a new position in Zimmer Biomet in the 3rd quarter worth about $31,000. Mather Group LLC. bought a new position in shares of Zimmer Biomet in the third quarter worth approximately $36,000. Finally, Headlands Technologies LLC bought a new position in shares of Zimmer Biomet in the 2nd quarter worth $37,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 0.4%

Zimmer Biomet stock opened at $85.67 on Thursday. Zimmer Biomet Holdings, Inc. has a 12 month low of $84.91 and a 12 month high of $114.44. The stock has a fifty day simple moving average of $91.18 and a two-hundred day simple moving average of $96.08. The firm has a market cap of $16.98 billion, a price-to-earnings ratio of 21.21, a PEG ratio of 2.19 and a beta of 0.62. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The business had revenue of $2 billion for the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter in the prior year, the business earned $1.74 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is presently 23.76%.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZBH. TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, January 21st. Sanford C. Bernstein upped their price target on Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research report on Friday, January 9th. Royal Bank Of Canada decreased their price objective on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, November 6th. Finally, UBS Group cut their price objective on Zimmer Biomet from $88.00 to $86.00 and set a “sell” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $107.24.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.